Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announced that its CEO and Chairman, John Yu, MD, will deliver a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is scheduled to take place from Sept. 14-16, 2026, at the Lotte New York Palace Hotel.
This presentation comes at a critical time for the company as it advances its lead candidate, ENV-105, an antibody designed to target CD105, a protein implicated in drug resistance and disease relapse. By targeting CD105, ENV-105 aims to reverse resistance and restore the efficacy of standard therapies across multiple cancer types. The company's approach leverages structural biology to address two major challenges in oncology: drug resistance and immune suppression.
The significance of this presentation lies in the exposure it provides to the investment community, potentially attracting partnerships and funding necessary to accelerate clinical development. For patients, the implications are profound: if ENV-105 succeeds, it could offer new hope for those with cancers that have become resistant to current treatments, a major unmet medical need.
According to the American Cancer Society, drug resistance is a leading cause of cancer treatment failure, contributing to relapse and poor survival rates. Kairos Pharma's focus on CD105 is particularly noteworthy because CD105 is overexpressed in tumor vasculature and has been linked to poor prognosis in several cancers, including breast, lung, and colorectal cancers. By inhibiting CD105, ENV-105 may not only combat resistance but also enhance the body's immune response against tumors.
The conference presentation will allow Kairos Pharma to showcase its scientific platform and clinical progress to a broad audience of investors, analysts, and industry experts. This visibility is crucial for a clinical-stage biopharmaceutical company seeking to advance its pipeline and ultimately bring innovative therapies to patients.
Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression. The company's lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
For more information about Kairos Pharma and its latest updates, visit the company's newsroom at https://ibn.fm/KAPA. The full press release can be viewed at https://ibn.fm/NrBQD.
